According to our analysis, MMDs were mostly (N = 24/21 RCTs; 72.7%) used as a primary outcome to quantify the efficacy of anti-CGRP MAbs in preventing migraines and to eventually gain their approval. This evidence concerns the gene CALCA and migraine disorder.